Hims & Hers launches weight-loss drugs in Australia
Hims & Hers Health Inc (HIMS) launched GLP-1 weight-loss drugs and other treatments in Australia via its Pilot platform. The company acquired Eucalyptus, an Australian digital health platform, earlier in 2026. Hims aims to expand its services and targets $6.5 billion in revenue by 2030, though international growth has impacted gross margins. According to the company, international business has increased subscriptions and monthly revenue per subscriber by 21% year-over-year.
How this was made
The 30-second read
Why it matters
The launch could accelerate subscriber growth and diversify revenue, but margin pressure may increase due to international rollout costs.
Market read
The announcement provides a fresh catalyst for HIMS, potentially influencing its stock price and sector sentiment.
What to watch
Regulatory approvals and reimbursement frameworks in Australia could delay revenue realization.
Background
Hims & Hers recently acquired Australian digital health platform Eucalyptus, gaining the Pilot brand for men’s health.
Ticker impact
Hims & Hers announced the launch of GLP-1 weight‑loss drugs and other treatments in Australia via its Pilot platform.
Potential upside as investors price in international growth.
First‑time product launch in a large market; early‑stage but aligns with company’s expansion strategy.
Market effects
Highlights growth potential for telehealth and digital health providers expanding into international markets.
Adds competitive pressure to Australian telehealth firms and may attract local investors.
Signals broader trend of US telehealth firms seeking overseas expansion.
Counterpoint
The launch may strain margins and dilute focus on core US operations, limiting upside.
Key entities
- ExecutiveTim Doyle
Senior Vice President at Hims & Hers, former CEO of Eucalyptus.
